Remove 2010 Remove Clinical Trials Remove Consumption Remove Terpenes
article thumbnail

Best strains and terpenes for pain management

The Cannigma

There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. The best type of cannabis for dealing with chronic pain tends to be type I or type II strain with a terpene profile that includes linalool, pinene, beta-caryophyllene, limonene, or myrcene. Can topical terpenes alone help with pain?

Terpenes 111
article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

In 2010, another pre-clinical study was also conducted on mice, and published in the American Journal of Hospice and Palliative Care. All these findings correlate with the conclusions of the scientists who were involved in the mice study from 2010. What is the best strain for ALS?

Strains 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). However, from 2010, a dramatic increase is observable in articles about medicinal cannabis in the publications under analysis. Google Scholar.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).